Pharmacovigilance Consulting Services: Outsource or Retain?

Pharmacovigilance Consulting Services: What to Outsource and What to Retain

A company may outsource pharmacovigilance activities to gain expertise, manage increasing workloads, or support expansion into new markets. The arrangement may work well until a safety issue, inspection request, or missed timeline reveals that ownership is unclear.

Pharmacovigilance consulting services should therefore be selected based on what can be delegated effectively and what the organization must continue to govern, review, and explain.

Key Takeaway

A controlled outsourcing model delegates suitable activities while retaining internal ownership of the PV system, safety decisions, regulatory obligations, vendor oversight, data access, and escalation.

What Pharmacovigilance Consulting Services Can Cover

External support can address a single capability gap or a broader operating need. Common areas include ICSR operations, literature monitoring, reconciliation, aggregate reporting, regulatory intelligence, PSMF maintenance, training, audits, and local pharmacovigilance coverage.

Before selecting a provider, define whether the requirement is driven by workload, missing expertise, geographic expansion, system limitations, or independent review. A vague scope such as "support our PV activities" is difficult to price, govern, and assess.

Which PV Activities May Be Outsourced?

Repeatable, resource-intensive, technology-dependent, or periodic activities are often suitable for external support. These may include case intake and processing, literature screening, database administration, reconciliation, report preparation, and selected medical-writing activities.

Specialist support may also be useful for inspection preparation, training development, PSMF updates, and Local Person responsible for Pharmacovigilance, or Local PVoI support, where applicable.

The activity category alone should not determine the decision. Case processing may be procedural, but a complex portfolio can require sponsor-specific coding conventions, escalation criteria, and detailed product knowledge. The model must therefore account for training, knowledge transfer, quality review, and escalation.

What Must Remain Under Internal Control?

A marketing authorization holder may subcontract pharmacovigilance activities, but regulatory responsibility for the PV system remains with the MAH. This includes oversight of safety data, regulatory submissions, signal and benefit-risk decisions, vendor performance, data access, documentation, and the accuracy of the PSMF.

Internal control should cover system governance, benefit-risk and regulatory decisions, PV vendor oversight, safety-data access, escalation, and confirmation that documented arrangements match actual operations.

A provider may perform an activity, prepare an assessment, or draft a submission. The organization should still have an internal owner who understands the process, reviews performance, and can explain how outputs are controlled.

Without clear internal ownership, delayed case exchanges, inconsistent safety decisions, inaccessible records, or unresolved vendor issues may remain unnoticed until an inspection or regulatory deadline.

When a Hybrid Pharmacovigilance Model Works Best

A hybrid pharmacovigilance model is often more effective than treating outsourcing as an all-or-nothing decision.

Decision factor	External support may suit	Internal or hybrid control may suit
Work pattern	High-volume, variable, or periodic work	Continuous system governance
Decision type	Standardized execution	Product-specific scientific judgment
Capability	Specialist technology or regional expertise	Institutional and portfolio knowledge
Regulatory impact	Drafting and coordination	Final decisions and accountability

For example, an organization may outsource case processing and literature surveillance while retaining signal conclusions, benefit-risk oversight, vendor governance, and final regulatory decisions internally.

To reduce risk, each outsourced activity should have a named internal owner, defined review requirements, clear escalation pathways, and documented access to supporting records.

How to Evaluate a PV Provider

Review the delivery team, not only the commercial proposal. Examine therapeutic-area experience, staff continuity, training controls, subcontracting, capacity planning, business continuity, and quality-system maturity.

MHRA GPvP guidance emphasizes that safety data, source records, and derived datasets must remain accessible to the MAH during inspection requests, service transfers, and contract termination. Data ownership, retention, migration, export formats, and retrieval responsibilities should therefore be defined before work begins.

Scenario-based evaluation can reveal more than a standard presentation. Ask how the provider would manage a serious quality issue, missed exchange timeline, sudden case-volume increase, or urgent safety escalation.

Make the Agreement Operationally Specific

An outsourcing arrangement may appear clear at the start but become difficult to manage when responsibilities, timelines, or data-access requirements are not defined in operational terms.

The agreement should therefore specify who performs, reviews, approves, documents, and escalates each activity, including how deviations, CAPAs, inspections, transitions, and contract termination will be managed.

A responsibility matrix should show who performs, reviews, approves, supplies information, and receives escalation for each activity. The PSMF should also reflect significant subcontracting arrangements, products, territories, and current operating practice.

Review the Model as the PV System Changes

An early clinical-stage outsourcing model may no longer suit commercialization, market expansion, system change, or sustained case-volume growth.

Governance reviews should assess whether the scope remains appropriate, capacity is sufficient, and knowledge transfer is effective. They should also confirm that agreements, SOPs, training records, and the PSMF remain aligned.

Build a Controlled PV Outsourcing Model

Successful PV outsourcing is not measured only by the work completed by the provider. It also depends on whether the organization retains clear ownership, timely access to evidence, effective oversight, and control of regulatory decisions.

PVCON Consulting supports pharmaceutical, biotechnology, CRO, and medical device organizations through specialized services including GxP Audits, PV Audits, GCP Audits, Other GxP Audits, Pharmacovigilance Consulting, PV Quality Management System support, PvOIC services, Regulatory Intelligence, Medical Writing, Aggregate Report Writing, Clinical Safety Documents, RMP and REMS Writing, PSMF Management, and Training & Upskilling initiatives such as Training Matrix, Regulatory Compliance Training, PV Boot Camp, and Customized Learnings.

Our expertise helps organizations strengthen drug safety operations, improve inspection and audit readiness, and keep PSMF documentation compliant, accurate, and aligned with real-world PV system practices and regulatory expectations.

If you are deciding which activities to outsource, retain internally, or manage through a controlled hybrid structure, you can contact our team or learn more about us.